A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma
Open Access
- 8 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 12 (10), 1071-1077
- https://doi.org/10.1093/neuonc/noq071
Abstract
The objectives of this study were to determine the safety and efficacy of polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC) when added to radiation and temozolomide (TMZ) in adults with newly diagnosed glioblastoma (GB). Patients received external beam radiation with concurrent TMZ (75 mg/m2/day) followed by adjuvant TMZ (150–200 mg/m2/day for 5 consecutive days once every 9 weeks) and intramuscular poly-ICLC (20 mg/kg/dose given 3× per week for weeks 2–8). An adjuvant cycle was operationally defined as 9 weeks and patients continued adjuvant therapy until toxicity or disease progression. Ninety-seven patients were enrolled (60 men) with a median age of 56 years (range 21–85) and Karnofsky performance status of 90% (range 60%–100%). Fourteen patients did not start adjuvant treatment. Common treatment-related Grade 3–4 toxicities included neutropenia (20.6%), leukopenia (16.5%), thrombocytopenia (9%), and rash (1%). The entire cohort had a median survival of 17.2 months (95% CI: 15.5–19.3 months) with survival at 12, 18, and 24 months of 73.2%, 47.4%, and 29.9%. For subjects 18–70 years old, median overall survival was 18.3 months (95% CI: 15.9–19.8 months), as compared with 14.6 (95% CI: 13.2–16.8) reported by the EORTC 26981/22981 trial. These results demonstrate that poly-ICLC can be added to standard radiation and TMZ in patients with newly diagnosed GB without additional significant toxicities. Survival data at 12 and 18 months suggest that this may improve the efficacy of chemoradiation and adjuvant TMZ in this patient population.Keywords
This publication has 25 references indexed in Scilit:
- Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor EffectsCancer Research, 2009
- Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II TrialJournal of Clinical Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasJournal of Neuro-Oncology, 2008
- Double‐stranded RNA mediates interferon regulatory factor 3 activation and interleukin‐6 production by engaging Toll‐like receptor 3 in human brain astrocytesImmunology, 2008
- Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case studyNeuro-Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Long-term Treatment of Malignant Gliomas with Intramuscularly Administered Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose: An Open Pilot StudyNeurosurgery, 1996
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958